The 2021 approval by regulatory agencies of belimumab, a B lymphocyte stimulator (BLyS) inhibitor, and the 2022 approval of anifrolumab, a type I interferon inhibitor, has increased the therapeutic ...
Novo Nordisk’s once-a-day sickle cell disease drug etavopivat cut the rate of pain crises in a yearlong mid-stage study.
In the phase 3 Essence trial, a once-weekly dose of semaglutide 2.4 mg helped to improve liver fibrosis with no worsening of steatohepatitis and to resolve steatohepatitis with no worsening of ...
Additional positive data presented in a late-breaker poster by Pentara and colleagues titled “Additional Analysis of a 52-Week Phase II Trial of Neuromodulation of the Default Mode Network to ...
Credit: Art_Photo via Shutterstock. A Phase II clinical trial evaluating Sinaptica Therapeutics’ neuromodulation device in Alzheimer’s disease has hit its primary and key secondary endpoints. The ...
Abstract: This paper introduces a novel self-subtracted RLG current sensor (SSRLGCS ... the full waveform or DC information of the inductor current, facilitating modulation or phase current balancing, ...
necessitating phase modulation. Enhancing the differential phase of the AGG through modulation can significantly elevate the measurement accuracy and expand the operational envelope of gravity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback